ME 23ANDME HLDG CO

23andMe Survey Shows Majority of People Less Stressed About Their Health During This Holiday Season

23andMe Survey Shows Majority of People Less Stressed About Their Health During This Holiday Season

-14 percent of those surveyed say they’re stressed, compared to more than 47 percent in 2020

-Under 20 percent of those surveyed said COVID-19 would interfere with their traditional holiday plans; down from 62 percent in 2020

-However, most respondents still have some concern about their overall health, with 77 percent of those surveyed indicating they still feel some sort of negativity around their health

SUNNYVALE, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported survey results on how US adults are feeling about their health this holiday season. According to the survey*, most people in the US report feeling less stressed or anxious about their health this year compared to earlier in the pandemic, and many have returned to their traditional holiday celebrations.

In this third holiday under the shadow of COVID-19, people appear to have adjusted to the new normal and are more optimistic about their health.

However, most people are still concerned about their overall health, with 77 percent of those surveyed indicating they still feel some sort of negativity around their health.

Other highlights from the survey include:

  • 14% of those surveyed said they were more stressed this year compared to last, compared to more than 47% in 2020**
  • Similarly, only about 5% of those surveyed said they were more depressed this year compared to last year, compared to almost 32% in 2020
  • The percentage of respondents who feel less connected to friends and family dropped from 48% in 2020 to just 5% in 2022
  • Only about 17% of those surveyed said they would not be having a traditional holiday this year, compared to 62% in 2020
  • Almost 50% of the respondents who said they’re focused on their health also said they planned to make healthy lifestyle changes in the new year, with a focus on their diet and weight

More details can be found on the .

Methodology

*This online survey was designed by 23andMe and conducted through SurveyMonkey® from November 8th-9th, 2022 among a national sample of 1,109 adults ages 18 and up. Respondents for this survey were selected from people who take surveys on the SurveyMonkey platform each day. Data for this time period have been weighted for age, race, sex, education, and geography using the Census Bureau’s American Community Survey to reflect the demographic composition of the United States. The modeled error estimate for this survey is plus or minus 3.5 percentage points.

**23andMe commissioned a .

About 23andMe

23andMe is a genetics-led consumer healthcare and therapeutics company empowering a healthier future. For more information, please visit .

Contacts

Investor Relations Contact:

Media Contact:



EN
01/12/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on 23ANDME HLDG CO

Pierre FerraguÊ
  • Pierre FerraguÊ

The Tech Infrastructure Quarterly Bible 1Q25

We publish today our comprehensive quarterly bible: 237 pages of detailed analyses on what happened in the last 3 months, and how we interpret it, in light of our current convictions. The first section acts as a PM summary, outlining our key findings, and latest thoughts on the semi cycle, in 6 slides.

 PRESS RELEASE

23andMe Reaches Agreement for Sale of Business to TTAM Research Instit...

23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process TTAM Commits to Comply with Company’s Privacy Policy and All Applicable Laws TTAM Commits to Adopting Additional Consumer Protections and Privacy Safeguards to Enhance Protections for Customer Data and Privacy No Changes to 23andMe’s Privacy Policy or Consumer Genome Services Transaction Subject to Court Approval SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics ...

 PRESS RELEASE

23andMe Announces Intent to Voluntarily Delist from Nasdaq and Deregis...

23andMe Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC SAN FRANCISCO, May 27, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics and biotechnology company, today announced its intention to file a Form 25 Notification of Delisting with the Securities and Exchange Commission (the “SEC”) on or about June 6, 2025, which will remove its securities from listing and registration on Nasdaq. Nasdaq previously suspended the trading of 23andMe’s Class A common stock, $0.0001 par value per share (the “Common...

 PRESS RELEASE

Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in...

Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised Sale Regeneron Commits to Comply with Company’s Privacy Policy and All Applicable Law; No Changes to 23andMe’s Privacy Policy or Consumer Genome Services Transaction Subject to Court Approval SAN FRANCISCO, May 19, 2025 (GLOBE NEWSWIRE) --  23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics and biotechnology company, today announced that it has entered into a definitive agreement for the sale of 23andMe to Regeneron Pharmaceuticals, Inc. (“Regeneron”) (NASDAQ: RE...

 PRESS RELEASE

23andMe Provides Update Regarding Court-Supervised Sale Process

23andMe Provides Update Regarding Court-Supervised Sale Process SAN FRANCISCO, April 18, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics and biotechnology company, today provided additional information on the protections in place for customer data in connection with the court-supervised sale of the Company’s assets. The process is being led by the Special Committee of the Company’s Board of Directors, which will evaluate potential acquisition bids, and supervised by the U.S. Bankruptcy Court for the Eastern District of Misso...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch